NASDAQ:GRFS - GRIFOLS S A/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GRIFOLS S A/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $22.97 +0.59 (+2.64 %) (As of 12/6/2019 04:00 PM ET) Add Compare Today's Range$22.48Now: $22.97▼$23.6050-Day Range$20.65MA: $21.81▼$22.9752-Week Range$17.42Now: $22.97▼$23.60Volume1.83 million shsAverage Volume1.17 million shsMarket Capitalization$15.79 billionP/E Ratio19.63Dividend Yield1.52%Beta1.06 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GRFS Previous Symbol CUSIPN/A CIK1438569 Webhttp://www.grifols.com/ Phone212-969-3335Debt Debt-to-Equity Ratio1.30 Current Ratio2.62 Quick Ratio0.96Price-To-Earnings Trailing P/E Ratio19.63 Forward P/E Ratio18.38 P/E Growth1.43 Sales & Book Value Annual Sales$5.30 billion Price / Sales2.98 Cash Flow$1.57 per share Price / Cash Flow14.65 Book Value$8.07 per share Price / Book2.85Profitability EPS (Most Recent Fiscal Year)$1.17 Net Income$704.63 million Net Margins11.12% Return on Equity13.58% Return on Assets5.04%Miscellaneous Employees21,230 Outstanding Shares687,550,000Market Cap$15.79 billion Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive GRFS News and Ratings via Email Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GRFS Rates by TradingView GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions What is GRIFOLS S A/S's stock symbol? GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS." How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S? GRIFOLS S A/S announced a semi-annual dividend on Thursday, October 31st. Stockholders of record on Tuesday, December 3rd will be given a dividend of $0.169 per share on Wednesday, December 11th. This represents a dividend yield of 1.3%. The ex-dividend date is Monday, December 2nd. This is an increase from GRIFOLS S A/S's previous semi-annual dividend of $0.15. View GRIFOLS S A/S's Dividend History. When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work? GRIFOLS S A/S's stock split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were distributed to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split. When is GRIFOLS S A/S's next earnings date? GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for GRIFOLS S A/S. What price target have analysts set for GRFS? 4 brokers have issued 12-month price objectives for GRIFOLS S A/S's stock. Their forecasts range from $19.00 to $22.50. On average, they anticipate GRIFOLS S A/S's stock price to reach $20.75 in the next year. This suggests that the stock has a possible downside of 9.7%. View Analyst Price Targets for GRIFOLS S A/S. What is the consensus analysts' recommendation for GRIFOLS S A/S? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GRIFOLS S A/S. Has GRIFOLS S A/S been receiving favorable news coverage? Media coverage about GRFS stock has trended very negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GRIFOLS S A/S earned a media sentiment score of -3.6 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for GRIFOLS S A/S. Are investors shorting GRIFOLS S A/S? GRIFOLS S A/S saw a decline in short interest in the month of October. As of October 15th, there was short interest totalling 2,490,000 shares, a decline of 7.4% from the September 15th total of 2,690,000 shares. Based on an average trading volume of 1,270,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.0% of the shares of the stock are short sold. View GRIFOLS S A/S's Current Options Chain. Who are some of GRIFOLS S A/S's key competitors? Some companies that are related to GRIFOLS S A/S include Allergan (AGN), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG) and Teva Pharmaceutical Industries (TEVA). What other stocks do shareholders of GRIFOLS S A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), Allergan (AGN), Teva Pharmaceutical Industries (TEVA), Neurocrine Biosciences (NBIX), Nektar Therapeutics (NKTR), Southern Copper (SCCO), Celgene (CELG), NVIDIA (NVDA), Supernus Pharmaceuticals (SUPN) and Alibaba Group (BABA). Who are GRIFOLS S A/S's key executives? GRIFOLS S A/S's management team includes the folowing people: Mr. Raimon Grifols Roura, Co-CEO & Exec. Director (Age 55)Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)Mr. Víctor Grífols Deu, Co-CEO & Exec. Director (Age 42)Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs Who are GRIFOLS S A/S's major shareholders? GRIFOLS S A/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Pictet Asset Management Ltd. (1.15%), First Trust Advisors LP (0.40%), Soros Fund Management LLC (0.30%), Millennium Management LLC (0.29%), Man Group plc (0.22%) and Beck Mack & Oliver LLC (0.17%). Which major investors are selling GRIFOLS S A/S stock? GRFS stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Banco de Sabadell S.A, Soros Fund Management LLC, CWM LLC, Beck Mack & Oliver LLC, CIBC Asset Management Inc, Lenox Wealth Management Inc. and Crossmark Global Holdings Inc.. Which major investors are buying GRIFOLS S A/S stock? GRFS stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Pictet Asset Management Ltd., Point72 Asset Management L.P., Barclays PLC, CIBC Private Wealth Group LLC, Squarepoint Ops LLC, Voloridge Investment Management LLC and State Street Corp. How do I buy shares of GRIFOLS S A/S? Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is GRIFOLS S A/S's stock price today? One share of GRFS stock can currently be purchased for approximately $22.97. How big of a company is GRIFOLS S A/S? GRIFOLS S A/S has a market capitalization of $15.79 billion and generates $5.30 billion in revenue each year. The biotechnology company earns $704.63 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 21,230 workers across the globe.View Additional Information About GRIFOLS S A/S. What is GRIFOLS S A/S's official website? The official website for GRIFOLS S A/S is http://www.grifols.com/. How can I contact GRIFOLS S A/S? GRIFOLS S A/S's mailing address is 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 212-969-3335 or via email at [email protected] MarketBeat Community Rating for GRIFOLS S A/S (NASDAQ GRFS)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 277 (Vote Outperform)Underperform Votes: 385 (Vote Underperform)Total Votes: 662MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/7/2019 by MarketBeat.com StaffFeatured Article: Understanding each part of a balance sheet